A phase I, open-label, dose-escalation, multidose study of CDX-1307, a mannose receptor-targeted hCG-beta vaccine, in patients with incurable locally advanced or metastatic breast, colorectal, pancreatic, bladder and ovarian cancer.
Phase of Trial: Phase I
Latest Information Update: 23 Jul 2010
At a glance
- Drugs CDX 1307 (Primary)
- Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- 23 Jul 2010 Actual end date (1 Dec 2009) added as reported by ClinicalTrials.gov.
- 23 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Oct 2009 Positive results were presented at the 24th Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTc).